An efficient method to make human monoclonal antibodies from memory B cells: Potent neutralization of SARS coronavirus

Nature Medicine

Volumn 10, Issue 8, 2004, Pages 871-875

  Traggiai, Elisabetta ^a   Becker, Stephan ^b   Subbarao, Kanta ^c   Kolesnikova, Larissa ^b   Uematsu, Yasushi ^d   Gismondo, Maria Rita ^e   Murphy, Brian R ^c   Rappuoli, Rino ^d   Lanzavecchia, Antonio ^a  

^a INSTITUTE FOR RESEARCH IN BIOMEDICINE   (Switzerland)

^b PHILIPPS UNIVERSITY MARBURG   (Germany)

^c NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^d CHIRON VACCINES   (Italy)

^e UNIVERSITY OF MILAN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

MONOCLONAL ANTIBODY; PROTEIN P35;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY PRODUCTION; ARTICLE; B LYMPHOCYTE; CELL IMMORTALIZATION; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; EPSTEIN BARR VIRUS; HUMAN; HUMAN CELL; IMMUNOELECTRON MICROSCOPY; LYMPHOCYTE TRANSFORMATION; MEMORY CELL; MOUSE; NONHUMAN; PASSIVE IMMUNIZATION; PRIORITY JOURNAL; SARS CORONAVIRUS; VIRUS NEUTRALIZATION; VIRUS REPLICATION;

ADULT; ALPHA-MACROGLOBULINS; ANIMALS; ANTIBODIES, MONOCLONAL; B-LYMPHOCYTES; CERCOPITHECUS AETHIOPS; DISEASE MODELS, ANIMAL; DNA PRIMERS; ENZYME-LINKED IMMUNOSORBENT ASSAY; HERPESVIRUS 4, HUMAN; HUMANS; IMMUNIZATION, PASSIVE; IMMUNOLOGIC MEMORY; MEMBRANE GLYCOPROTEINS; MICE; MICROSCOPY, IMMUNOELECTRON; NEUTRALIZATION TESTS; POLYMERASE CHAIN REACTION; SEVERE ACUTE RESPIRATORY SYNDROME; TRANSFORMATION, GENETIC; VERO CELLS; VIRAL ENVELOPE PROTEINS;

ANIMALIA; CORONAVIRUS; HUMAN HERPESVIRUS 4; RNA VIRUSES; SARS CORONAVIRUS;

EID: 4043154176     PISSN: 10788956     EISSN: None     Source Type: Journal    
DOI: 10.1038/nm1080     Document Type: Article

References (30)

1. Behring, E. & Kitasato, S. [On the development of immunity to diphtheria and tetanus in animals]. Dtsch Med. Wochenschr. 90, 2183 (1965).
2. Keller, M.A. & Stiehm, E.R. Passive immunity in prevention and treatment of infectious diseases. Clin. Microbiol. Rev. 13, 602-614 (2000).
3. Kohler, G. & Milstein, C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 256, 495-497 (1975).
4. Steinitz, M., Klein, G., Koskimies, S. & Makel, O. EB virus-induced B lymphocyte cell lines producing specific antibody. Nature 269, 420-422 (1977).
5. Kozbor, D. & Roder, J.C. Requirements for the establishment of high-titered human monoclonal antibodies against tetanus toxoid using the Epstein-Barr virus technique. J. Immunol. 127, 1275-1280 (1981).
6. Lanzavecchia, A. Antigen-specific interaction between T and B cells. Nature 314, 537-539 (1985).
7. Kozbor, D., Roder, J.C., Chang, T.H., Steplewski, Z. & Koprowski, H. Human antitetanus toxoid monoclonal antibody secreted by EBV-transformed human B cells fused with murine myeloma. Hybridoma 1, 323-328 (1982).
8. Karpas, A., Dremucheva, A. & Czepulkowski, B.H. A human myeloma cell line suitable for the generation of human monoclonal antibodies. Proc. Natl. Acad. Sci. USA 98, 1799-1804 (2001).
9. Jones, P.T., Dear, P.M., Foote, J., Neuberger, M.S. & Winter, G. Replacing the complementarity-determining regions in a human antibody with those from a mouse. Nature 321, 522-525 (1986).
10. McCafferty, J., Griffiths, A.D., Winter, G. & Chiswell, D.J. Phage antibodies: filamentous phage displaying antibody variable domains. Nature 348, 552-554 (1990).
11. Green, L.L. Antibody engineering via genetic engineering of the mouse: XenoMouse strains are a vehicle for the facile generation of therapeutic human monoclonal antibodies. J. Immunol. Methods 231, 11-23 (1999).
12. Brekke, O.H. & Sandlie, I. Therapeutic antibodies for human diseases at the dawn of the twenty-first century. Nat. Rev. Drug Discov. 2, 52-62 (2003).
13. Johnson, S. et al. Development of a humanized monoclonal antibody (MEDI-493) with potent in vitro and in vivo activity against respiratory syncytial virus. J. Infect. Dis. 176, 1215-1224 (1997).
14. Drosten, C. et al. Identification of a novel coronavirus in patients with severe acute respiratory syndrome. N. Engl. J. Med. 348, 1967-1976 (2003).
15. Ksiazek, T.G. et al. A novel coronavirus associated with severe acute respiratory syndrome. N. Engl. J. Med. 348, 1953-1966 (2003).
16. Rota, P.A. et al. Characterization of a novel coronavirus associated with severe acute respiratory syndrome. Science 300, 1394-1399 (2003).
17. Fouchier, R.A. et al. Aetiology: Koch's postulates fulfilled for SARS virus. Nature 423, 240 (2003).
18. Poutanen, S.M. et al. Identification of severe acute respiratory syndrome in Canada. N. Engl. J. Med. 348, 1995-2005 (2003).
19. Lee, N. et al. A major outbreak of severe acute respiratory syndrome in Hong Kong. N. Engl. J. Med. 348, 1986-1994 (2003).
20. Donnelly, C.A. et al. Epidemiological determinants of spread of causal agent of severe acute respiratory syndrome in Hong Kong. Lancet 361, 1761-1766 (2003).
21. + dual receptor B cells are present in the human peripheral repertoire. J. Exp. Med. 181, 1245-1250 (1995).
22. Hartmann, G. & Krieg, A.M. Mechanism and function of a newly identified CpG DNA motif in human primary B cells. J. Immunol. 164, 944-953 (2000).
23. Bernasconi, N.L., Traggiai, E. & Lanzavecchia, A. Maintenance of serological memory by polyclonal activation of human memory B cells. Science 298, 2199-2202 (2002).
24. Subbarao, K. et al. Prior infection and passive transfer of neutralizing antibody protect mice from subsequent infection with SARS coronavirus. J. Virol. 78, 3572-3577 (2004).
25. Gebauer, F. et al. Residues involved in the antigenic sites of transmissible gastroenteritis coronavirus S glycoprotein. Virology 183, 225-238 (1991).
26. Graham, B.S., Perkins, M.D., Wright, P.F. & Karzon, D.T. Primary respiratory syncytial virus infection in mice. J. Med. Virol. 26, 153-162 (1988).
27. Stack, A.M. et al. Primary respiratory syncytial virus infection: pathology, immune response, and evaluation of vaccine challenge strains in a new mouse model. Vaccine 18, 1412-1418 (2000).
28. Becker, S., Feldmann, H., Will, C. & Slenczka, W. Evidence for occurrence of filovirus antibodies in humans and imported monkeys: do subclinical filovirus infections occur worldwide? Med. Microbiol. Immunol. (Berl.) 181, 43-55 (1992).
29. Karber, G. 50% end-point calculation. Arch. Exp. Pathol. Pharmak. 162, 480-483 (1931).
30. Perri, S. et al. An alphavirus replicon particle chimera derived from Venezuelan equine encephalitis and Sindbis viruses is a potent gene-based vaccine delivery vector. J. Virol. 77, 10394-10403 (2003).